Direct Acting Antiviral-Post Authorization Safety Study

Screening Inclusion Criteria:

- Current participant in TARGET-HCC

- Adults, age ≥18 years

- First diagnosis of HCC (mixed HCC/cholangiocarcinoma may be included). Diagnosis may
be histological/cytological and/or radiological.

- BCLC Stage A

- Underwent, undergoing, or planned to undergo therapy for HCC, with exception that
transplant as prior or planned treatment for HCC is excluded.

- HCV RNA positive

Screening Exclusion Criteria:

- Inability to provide informed consent

- HCC-free imaging (as defined in Section 9.1.1) after treatment of initial HCC prior to
Screening (see Section 9.2.9 for imaging details)

- Prior liver transplantation

- Hepatitis B Virus (HBV) surface antigen positive (HBsAg)

- Previously treated with direct-acting antiviral agents (not DAA-naïve); Note that
prior (peg)IFN and/or ribavirin therapy is allowed

Enrollment Inclusion Criteria:

- Continued participation in TARGET-HCC

- No recurrence or progression of initial HCC beyond BCLC Stage A prior to
Enrollment/Baseline

- HCC-free imaging (as defined in Section 9.1.1) at Enrollment/Baseline (see Section
9.2.9 for imaging details; participants may remain in Screening until an HCC-free
image is obtained)

- Remains DAA-naïve (prior therapy with (peg)IFN and/or ribavirin is allowed)

Enrollment Exclusion Criteria:

- Liver transplantation since Screening